-
Start Preamble
Start Printed Page 43763
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the National Advisory Council for Complementary and Alternative Medicine (NACCAM) meeting.
The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.
A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussion could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council for Complementary and Alternative Medicine.
Date: September 12, 2008.
Closed: 8:30 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant applications and/or proposals.
Open: 11 a.m. to 4 p.m.
Agenda: Opening remarks by the Director of the National Center for Complementary and Alternative Medicine, presentation of a new research initiative, and other business of the Council.
Place: National Institutes of Health, Neuroscience Building, 6001 Executive Boulevard, Conference Rooms C & D, Bethesda, MD 20892.
Contact Person: Martin H. Goldrosen, PhD, Executive Secretary, National Center for Complementary, and Alternative Medicine, National Institutes of Health, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, (301) 594-2014.
The public comments session is scheduled from 3:30-4 p.m., but could change depending on the actual time spent on each agenda item. Each speaker will be permitted 5 minutes for their presentation. Interested individuals and representatives of organizations are requested to notify Dr. Martin H. Goldrosen, National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland, 20892, 301-594-2014, Fax: 301-480-9970. Letters of intent to present comments, along with a brief description of the organization represented, should be received no later than 5 p.m. on September 8, 2008. Only one representative of an organization may present oral comments. Any person attending the meeting who does not request an opportunity to speak in advance of the meeting may be considered for oral presentation, if time permits, and at the discretion of the Chairperson. In addition, written comments may be submitted to Dr. Martin H. Goldrosen at the address listed above up to ten calendar days (September 22, 2008) following the meeting.
Copies of the meeting agenda and the roster of members will be furnished upon request by contacting Dr. Martin H. Goldrosen, Executive Secretary, NACCAM, National Center for Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland 20892, 301-594-2014, Fax 301-480-9970, or via e-mail at naccames@mail.nih.gov.
In the interest of security, NIH has instituted stringent procedures for entrance into the building by nongovernment employees. Persons without a government I.D. will need to show a photo I.D. and sign-in at the security desk upon entering the building.
Start SignatureDated: July 21, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-17137 Filed 7-25-08; 8:45 am]
BILLING CODE 4140-01-P
Document Information
- Comments Received:
- 0 Comments
- Effective Date:
- 9/12/2008
- Published:
- 07/28/2008
- Department:
- National Institutes of Health
- Entry Type:
- Notice
- Document Number:
- E8-17137
- Dates:
- September 12, 2008.
- Pages:
- 43763-43763 (1 pages)
- PDF File:
- e8-17137.pdf
- Supporting Documents:
- » License Agreements; Start-Up Exclusive Evaluation Option: Activators of Human Pyruvate Kinase to Treat Cancer
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: National Institute of Nursing Research
- » Meetings: National Institute of Allergy and Infectious Diseases
- » Meetings: National Eye Institute
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: Center for Scientific Review
- » Meetings: Center for Scientific Review
- » Meetings: National Institute of Environmental Health Sciences
- » Meetings: National Human Genome Research Institute